Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma
Sponsor: Gilead Sciences
Terminated
closed to enrollment due to slow patient accrual
A PHASE1/PHASE2 clinical study on Follicular Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Gilead Sciences and has accumulated 9 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 4 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2017 — Mar 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- Weill Medical College of Cornell University
For direct contact, visit the study record on ClinicalTrials.gov .